<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00225654</url>
  </required_header>
  <id_info>
    <org_study_id>505</org_study_id>
    <nct_id>NCT00225654</nct_id>
  </id_info>
  <brief_title>The ELUTES Clinical Trial</brief_title>
  <acronym>ELUTES I</acronym>
  <official_title>The ELUTES Clinical Trial (European Evaluation of Paclitaxel Eluting Stent)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook Group Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook Group Incorporated</source>
  <brief_summary>
    <textblock>
      ELUTES is a European multicenter, randomized, controlled, triple-blinded study designed to&#xD;
      evaluate the ability of the Paclitaxel Eluting V-Flex Plus coronary stent to reduce&#xD;
      restenosis in the coronary artery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date>November 2001</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic in-stent % diameter stenosis and late loss at follow up.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lesion revascularization</measure>
  </secondary_outcome>
  <enrollment>192</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>coronary stent</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be eligible to undergo planned treatment of a single de novo lesion in a&#xD;
             native coronary artery.&#xD;
&#xD;
          -  Patient must be an acceptable candidate for coronary artery bypass surgery.&#xD;
&#xD;
          -  Patient or legal guardian must have signed informed consent.&#xD;
&#xD;
          -  Patient agrees to return at one month for an office visit to assess cardiovascular&#xD;
             status and at 6 months for an office visit to assess cardiovascular status and for a&#xD;
             diagnostic angiogram.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient must be less than 18 years old.&#xD;
&#xD;
          -  Patient has history of bleeding diathesis or coagulopathy or will refuse blood&#xD;
             transfusions.&#xD;
&#xD;
          -  Patient is simultaneously participating in another investigative interventional&#xD;
             cardiovascular device or drug study.&#xD;
&#xD;
          -  Patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or&#xD;
             stainless steel, or a sensitivity to contrast dye.&#xD;
&#xD;
          -  Women of child bearing potential.&#xD;
&#xD;
          -  Patient has other medical condition that may cause non-compliance with the protocol,&#xD;
             confound the results, or is associated with limited life expectancy.&#xD;
&#xD;
          -  Patient has been diagnosed with a myocardial infarction within 72 hours prior to&#xD;
             procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Gershlick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glenfield Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Sponsor</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <keyword>coronary artery</keyword>
  <keyword>stent</keyword>
  <keyword>drug eluting</keyword>
  <keyword>patency</keyword>
  <keyword>restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

